<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> deacetylase (HDAC) plays an important role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> and progression </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, inhibition of HDAC offers potential as an effective <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment regimen </plain></SENT>
<SENT sid="2" pm="."><plain>CG200745, (E)-N(1)-(3-(dimethylamino)<z:chebi fb="1" ids="26308">propyl</z:chebi>)-N(8)-hydroxy-2-((<z:chebi fb="6" ids="16482">naphthalene</z:chebi>-1-loxy)<z:chebi fb="36" ids="29309">methyl</z:chebi>)oct-2-enediamide, is a novel HDAC inhibitor presently undergoing a phase I clinical trial </plain></SENT>
<SENT sid="3" pm="."><plain>Enhancement of p53 acetylation by HDAC inhibitors induces cell cycle arrest, differentiation, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>The purpose of the present study was to investigate the role of p53 acetylation in the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell <z:hpo ids='HP_0011420'>death</z:hpo> caused by CG200745 </plain></SENT>
<SENT sid="5" pm="."><plain>CG200745-induced clonogenic cell <z:hpo ids='HP_0011420'>death</z:hpo> was 2-fold greater in RKO cells expressing <z:mp ids='MP_0002169'>wild-type</z:mp> p53 than in p53-deficient RC10.1 cells </plain></SENT>
<SENT sid="6" pm="."><plain>CG200745 treatment was also cytotoxic to PC-3 human <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> cells, which express <z:mp ids='MP_0002169'>wild-type</z:mp> p53 </plain></SENT>
<SENT sid="7" pm="."><plain>CG200745 increased acetylation of p53 lysine residues K320, K373, and K382 </plain></SENT>
<SENT sid="8" pm="."><plain>CG200745 induced the accumulation of p53, promoted p53-dependent transactivation, and enhanced the expression of MDM2 and p21(Waf1/Cip1) proteins, which are encoded by p53 target genes </plain></SENT>
<SENT sid="9" pm="."><plain>An examination of CG200745 effects on p53 acetylation using cells transfected with various p53 mutants showed that cells expressing p53 K382R mutants were significantly resistant to CG200745-induced clonogenic cell <z:hpo ids='HP_0011420'>death</z:hpo> compared with <z:mp ids='MP_0002169'>wild-type</z:mp> p53 cells </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, p53 transactivation in response to CG200745 was suppressed in <z:hpo ids='HP_0000001'>all</z:hpo> cells carrying mutant forms of p53, especially K382R </plain></SENT>
<SENT sid="11" pm="."><plain>Taken together, these results suggest that acetylation of p53 at K382 plays an important role in CG200745-induced p53 transactivation and clonogenic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>